2016 AGM it was clearly stated Discussions continue with global...

2016 AGM it was clearly stated

Discussions continue with global partner(s.) Increased interest post FDA Clearance. Timing of Letter Of Intent to be decided.

Signing of alliance/distribution agreement with global partners(s) for APAS

APAS Independence first Commercial sale by Global Alliance Partner


2017 AGM it was clearly stated

Signing of distribution agreement for APAS


2018 AGM is fast approaching

What will they say this year Signing of distribution agreement for APAS early 2019


I look at

Nanosonics with 299.2 million shares on issue a market cap of 1.1 billion and a shareprice of $ 3.60


Resapp Health with 659 Million shares on issue a market cap of 156 million and a share price of $ 0.22 doesn’t even have a product If we had a market cap of 156 million our share price would be $ 0.78


Then LBT with 201 million shares on issue and a market cap of 21 Million and a share price of $ 0.105


Something has to happen before AGM some objectives have to be met. I don’t want to hear about heavy lifting if you will, we need some results.


Some board members have been presiding over LBT for 12 years no less, unheard of these days and we have achieved very little, We need some more dynamic people on the board like Glenn Haifer and we need management to achieve some objectives.

We don’t even have a microbiologist on the board.

The current chair has been there since the original IPO at 0.20 and today we sit here at $ 0.105


If they had concentrated on getting the share price up, the options at 0.44 that expire in Nov and Dec might have been taken up which would of added 6 Million to the bottom line at a heathy price not these cap raises at 0.15


They can’t go to another AGM and present the next 12 months objectives when they haven’t achieved any from the year before.


CY18 Key Objectives as per 2017 AGM Presentation were

Extend APAS analysis modules Not done yet, That we know

Sales of APAS in Australia and NZ Only one sale

Sales of APAS in targeted European countries No sales achieved

Sales of APAS in USA No Sales achieved

Signing of distribution agreement Not done yet

FDA 510K supplement cleared for APAS Independence Not done yet

CE Marking for APAS No word

Market research for Woundvue Shelved

RAH 6 month review of Woundvue No word


These were all in the AGM presentation

12 months and none of the objectives have been met.


Its crunch time, time for results and it has to be before the AGM.

Current market cap lower than just the development cost of APAS.

It’s now or never. RESULTS must be forth coming


They have a wonderful machine, great AI, patented and proven and potential royalties of $60,000,000 on just 1500 machines. Never mind the profit share on the sales of the machine.

In my humble opinion.

60 million puts this young pup in the realms of a young cochlear.


The company has a future, but it has to start meeting objectives.